Results From ADVENTRX Vinorelbine Preclinical Studies Accepted for Presentation at AACR Annual Meeting
January 19 2006 - 10:00AM
PR Newswire (US)
SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) today announced that data from
preclinical studies of ANX-530 (vinorelbine emulsion) will be
presented at the 2006 American Association for Cancer Research
(AACR) Annual Meeting, April 1-5 in Washington DC. An abstract
entitled "A novel emulsion formulation of vinorelbine attenuates
venous toxicity while maintaining antitumor efficacy" will also be
published in the 2006 Proceedings of the American Association for
Cancer Research. The preclinical studies were conducted by
independent laboratories. "The presentation at AACR is a great
opportunity to present independent preclinical results for ANX-530.
We believe that the less vein-irritating IV formulation we are
developing can eventually become an attractive alternative to
currently available IV vinorelbine," said Evan M. Levine, ADVENTRX
president and CEO. "We remain on track to file an investigational
new drug (IND) application for ANX-530 in order to initiate a
single, marketing- enabling bioequivalency trial in the first half
of 2006." About ANX-530 ANX-530 is a novel emulsion formulation of
vinorelbine tartrate. Vinorelbine is a chemotherapeutic agent
indicated as a single agent or in combination with cisplatin for
treatment of advanced non-small cell lung cancer (NSCLC). The
Company plans to conduct a single bioequivalency study of ANX-530
as a marketing-enabling clinical trial, a plan that was recently
affirmed by the US Food and Drug Administration (FDA). The Company
currently plans to file an investigational new drug (IND)
application in the first half of 2006. The proposed clinical trial
will compare the bioequivalency of ANX-530 with that of vinorelbine
in patients with advanced solid tumors. In addition, the Company
plans to collect comparative data on vein irritation and other
safety parameters as secondary endpoints. About ADVENTRX ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on introducing new technologies for anticancer and
antiviral treatments that surpass the performance and safety of
existing drugs, by addressing significant problems such as drug
metabolism, toxicity, bioavailability and resistance. More
information can be found on the Company's Web site at
http://www.adventrx.com/. Forward Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last quarterly report on Form
10-Q, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024